Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05438485
Other study ID # HST21-NH03
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date August 27, 2021
Est. completion date October 20, 2023

Study information

Verified date September 2022
Source HemoShear Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The JUMP (Journey to Understand MMA and PA) Study is being conducted by HemoShear Therapeutics and AllStripes, a rare disease online research platform. JUMP is designed to accelerate understanding of the natural course of methylmalonic acidemia (MMA) and propionic acidemia (PA) disease and treatment for families, researchers, clinicians and industry. The study will collect and provide patient medical record information from multiple institutions for families to access in one place at no cost. AllStripes will remove identifying information like name and address from these medical records and aggregate this data for the HemoShear team to better understand the medical experience and progression of MMA and PA over time. In addition, academic researchers, healthcare practitioners and patient advocacy groups can apply to use the collective patient community data to answer specific research questions at no cost. HemoShear is collecting natural history data on MMA and PA because the company needs insight into the real-world experience of many patients to better understand the disease and be able to scientifically demonstrate whether the potential new treatment they are developing is effective in improving outcomes. This natural history study will include retrospective and prospective components. The retrospective component will consist of data abstracted from primarily electronic health records (eHR) and some paper records. The prospective component will include ongoing collection of medical records from enrolled participants, and participants may opt in to complete health-related questionnaires and an optional genetic testing sub-study. After signing informed consent, participants or their legal guardians will grant permission to AllStripes to collect their health records for data abstraction. Participants may opt into an optional no cost genetic testing sub-study. The JUMP (Journey to Understand MMA and PA) sub-study will help assess whether the genetic variant of the affected person may relate to disease severity and treatment response. Getting genetic testing will enable participants to understand the genetic mutation that causes their type of methylmalonic acidemia (MMA) or propionic acidemia (PA). Knowing the genetic mutations (whether from the MMUT, MMAA or MMAB gene or PCCA or PCCB) can help the impacted person, their caregivers and healthcare professionals understand the potential course of disease and select approaches to better manage the disease. The additional information will enable HemoShear and AllStripes to understand whether different genetic variants impact the disease journey and outcomes. A separate informed consent will be obtained for participating in the sub-study.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date October 20, 2023
Est. primary completion date October 20, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Participant or participant's legal guardian must provide signed, informed eConsent/eAssent prior to releasing health records or performing any study-related procedures. 2. Confirmed diagnosis of MMA or PA. 3. Reside in the US, Canada, or United Kingdom and have all medical records available for abstraction. Exclusion Criteria: 1. Participant or participant's legal guardian is unable to provide complete access to medical records.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Registry
Observational (Registry)

Locations

Country Name City State
Canada AllStripes Remote
United Kingdom AllStripes Remote
United States AllStripes San Francisco California

Sponsors (4)

Lead Sponsor Collaborator
HemoShear Therapeutics AllStripes Research Inc., Genome Medical, Prometrika, LLC

Countries where clinical trial is conducted

United States,  Canada,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Understanding of the natural course of methylmalonic acidemia (MMA) and propionic acidemia (PA) disease and treatment for families, researchers, clinicians and industry. 5 years
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05842837 - A Non-Interventional Post-Authorization Study of Carbaglu for the Treatment of Hyperammonemia Due to MMA and PA
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT05130437 - A Long-Term Extension Study to Evaluate the Safety and Clinical Activity of mRNA-3927 Phase 1/Phase 2
Recruiting NCT02890342 - Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic Acidemia
Completed NCT02426775 - Carglumic Acid in Methylmalonic Acidemia and Propionic Acidemia Phase 3
Terminated NCT04836494 - A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia Phase 1
Completed NCT03484767 - "The MaP Study": Mapping the Patient Journey in MMA and PA
Terminated NCT04732429 - Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia Phase 2
Recruiting NCT05040178 - An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
Recruiting NCT05769621 - A Retrospective Study to Characterize Participants With Propionic Acidemia
Completed NCT00645879 - Anaplerotic Therapy in Propionic Acidemia Phase 1
Recruiting NCT04176523 - Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach
Withdrawn NCT01341379 - Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate Phase 2
Completed NCT03159026 - Review of Charts From Amish/Mennonite Variant PA Patients
Recruiting NCT04159103 - Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia Phase 1/Phase 2